Prop 38 Eligibility Rules Spark Debate Over Whether Bond Funds Are Pre-Determined for Single UCLA Institute

Opponents of California Proposition 38 argue that the ballot measure’s highly specific eligibility requirements effectively guarantee that half of its research grant funding will flow to a single nonprofit entity, raising concerns about whether the bond was drafted to benefit a predetermined recipient rather than foster open scientific competition.

The measure authorizes state bonds to fund medical research infrastructure, but critics say the qualification criteria are so narrow that only the California Institute for Immunology and Immunotherapy (CIII) currently meets every statutory threshold. Robert Kaplan, a senior scholar at Stanford’s Clinical Excellence Research Center, and David Panush, a former senior health policy advisor to five state Senate presidents, lead the opposition campaign and describe the drafting as deceptive.

Under Prop 38, eligible institutions must have been established on or after Jan. 1, 2025, and control at least 200,000 square feet of research space. They must also hold an affiliation agreement with a University of California campus connected to a health system recording more than 35,000 inpatient admissions and 3.5 million outpatient visits annually. Additionally, applicants must demonstrate $250 million in identified philanthropic support and secure two separate $50 million commitments for designated research programs before receiving funds.

A UCLA spokesperson confirmed to CalMatters that among all nonprofit entities affiliated with the university, only CIII satisfies these stipulations. The institute became a nonprofit in 2022 and has received at least $120 million in donations from co-founder Gary K. Michelson, a billionaire inventor who serves as board chair. CIII operates within a research center owned by UCLA.

Proponents acknowledge CIII’s likely advantage but deny the measure is exclusionary. Robin Swanson, spokesperson for the Yes on 38 campaign, stated during a mid-September virtual news conference that while CIII would probably receive half the funds under current criteria, institutions affiliated with Stanford, Scripps Research, USC, and Cedars-Sinai could qualify for the remaining allocation. She framed the strict standards as a safeguard to ensure recipients are operationally prepared to deploy capital immediately upon bond passage.

Swanson emphasized that final eligibility determinations rest with the California Department of Public Health, not the campaign. However, opponents contend that delegating discretion to a state agency does not resolve the structural issue: the statutory language itself creates a de facto sole-source award mechanism for one portion of the funding pool.

Beyond eligibility concerns, the No on Prop 38 campaign challenges the underlying fiscal model. They argue that issuing general obligation bonds commits taxpayers to decades of debt service without any guaranteed return, as future revenue streams from publicly funded biomedical research remain speculative and historically difficult to capture for state coffers.

California voters have approved multiple health-related bond measures in recent years, including Proposition 2 in 2024 for behavioral health facilities and Proposition 1 in 2024 for veterans’ housing. Prop 38 differs significantly by tying disbursements to private philanthropy thresholds and institutional scale metrics rarely used in prior state research funding formulas.

The California Secretary of State’s office lists Prop 38 on the November 2026 ballot. Early voting begins October 5.